NCT01476839View on ClinicalTrials.gov

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 9, 2012

Primary Completion Date

July 24, 2021

Study Completion Date

May 31, 2024

Conditions

Recurrent Adult Hodgkin Lymphoma

Interventions

BIOLOGICAL

basiliximab

Given IV

DRUG

carmustine

Given IV

DRUG

etoposide

Given IV

DRUG

cytarabine

Given IV

DRUG

melphalan

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

autologous hematopoietic stem cell transplantation

Undergo autologous hematopoietic progenitor cell infusion

BIOLOGICAL

yttrium Y 90-labeled basiliximab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01476839 - Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter